Phaseline

Companies › Remedy

Remedy: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Midomafetamine
Sodium-dependent dopamine transporter releasing agent; Sodium-dependent serotonin transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent
SLC6A3, SLC6A4, SLC6A2Phase 2Post Traumatic Stress DisorderMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06044675MidomafetaminePhase 2Post Traumatic Stress DisorderPsychiatryMar 2027

Targets

SLC6A3 (1) SLC6A4 (1) SLC6A2 (1)

Companies with the same targets

Axsome Therapeutics Otsuka Resilient Pharmaceuticals Definium Therapeutics US Currax Pharmaceuticals AlgoTherapeutix CSPC ZhongQi Pharmaceutical Technology Primus Pharmaceuticals Gradalis Intra-Cellular Therapies

Companies built like this

Definium Therapeutics US Draig Therapeutics Kadence Bio HB BioTech Beckley Psytech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.